Pharmaceuticals, Biotechnology and Life Sciences
Data Show KEYTRUDA Monotherapy Significantly Reduced the Risk of Disease Progression or Death by 35% Compared with BV
Phase 2a Study of FX-322 for Sensorineural Hearing Loss Continues Enrollment at Multiple Sites Shares Top-Line Data from Exploratory Clinical…
BOSTON–(BUSINESS WIRE)–Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization impacting the…
DUBLIN–(BUSINESS WIRE)–The “Global Immunosuppressants API Market By Method (Synthetic Chemistry, Peptide chemistry, Fermentation, Chromatographic purification), By Application, By Type, By…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. today announced that new data supporting the clinical use of its portfolio of tissue and…
CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid…
AVROBIO’s optimized lentiviral vectors demonstrate significant glycogen reduction in the muscle and central nervous system of Pompe disease mouse model…
KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Mike Nally,…
Positive Phase 1 cosmetic clinical study results of BX001 in acne-prone skin reported; planned advance to Phase 2 study with…
Exicure had net income of $1.1 million for the quarter ended March 31, 2020 compared to a net loss of $5.3 million for the quarter ended March 31, 2019, reflecting a difference of $6.4 million.